Questions for week 2

Q1) Are any measurements being taken (e.g., changes of weight, diet, blood pressure, self-report questionnaires) within the two-month intervals?

Q2) What kind of variables have been found to be confounding for testing asthma drugs in the past (e.g., age, gender, etc)?.

Q3) Is the new treatment to be used for all kinds of asthma or just certain types (e.g., allergic, exercise-induced, etc) ? In the former case, are you considering dividing the ashtma patients by asthma-type?

a) In Analysing controlled trials with baseline and follow up measurements, it seems that linear regression does not fit the data well. Does this matter? b) Except gender, are there any other factors that have impacts on FVC? Or in other words, What decides the difference of FVC between male and female?

Q.1) Since FEV1 depends on multiple variables (e.g. age, sex, height) are the researchers planning to take these into account when they assign the two treatments? Q.2) What are they planning to do in case of possible drop outs? Q.3) What kind of treatment effect are the researchers anticipating?